Results 191 to 200 of about 823,307 (385)

Pancreatic ductal adenocarcinoma: long-term survival does not equal cure.

open access: yesSurgery, 2012
C. Ferrone   +12 more
semanticscholar   +1 more source

GRP78 Nanobody‐Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy

open access: yesAdvanced Science, EarlyView.
A GRP78 nanobody‐directed immunotoxin suppresses cancer progression and metastasis by enhancing antitumor immunity via STING pathway activation, offering a pan‐cancer‐targeted approach and immunotherapy combination strategy. Abstract The lack of targetable antigens poses a significant challenge in developing effective cancer‐targeted therapies.
Huifang Wang   +16 more
wiley   +1 more source

Adenocarcinoma in a small gastric polyp.A case report [PDF]

open access: bronze, 1962
L Bowden
openalex   +1 more source

PCSK9 Promotes the Malignancy of Triple‐negative Breast Cancer Cells by Reducing Cholesterol Levels at the Plasma Membrane to Activate EGFR and HER3

open access: yesAdvanced Science, EarlyView.
By decreasing cholesterol and lipid raft levels in the plasma membrane, proprotein convertase subtilisin/kexin type 9 (PCSK9) boosts human epidermal growth factor receptor 1 and 3 (EGFR and HER3) activation, driving tumor growth and metastasis in triple‐negative breast cancer (TNBC).
Tianhong Li, Renfei Wu, Kathy Qian Luo
wiley   +1 more source

Recent Advancements in Lung Cancer Metastasis Prevention Based on Nanostrategies

open access: yesAdvanced Science, EarlyView.
Metastasis is the leading cause of death in patients with lung cancer. Nanomedicine can be used to prepare efficient drug delivery systems owing to their advantages and plays an important role in the synergistic antimetastasis of lung cancer. This comprehensive review summarizes the emerging nanostrategies against lung cancer metastasis based on the ...
Fan Xu   +7 more
wiley   +1 more source

A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer

open access: yesAnnals of Gastroenterological Surgery, Volume 7, Issue 1, Page 81-90, January 2023., 2023
XELOXIRI neoadjuvant chemotherapy appears to be feasible and efficacious for patients with LARC. Although neoadjuvant XELOXIRI alone did not yield our expected pCR rate, the local recurrence rate, 3‐year DFS and measures of safety met current standards.
Chu Matsuda   +16 more
wiley   +1 more source

Evaluation of recurrence in gastric adenocarcinoma patients [PDF]

open access: bronze, 1966
Jan W. Kuzma, W. J. Dixon
openalex   +1 more source

Home - About - Disclaimer - Privacy